In short
Clinical trials investigating VELPATASVIR are studying its use in people with chronic hepatitis C virus infection. The trial data focus on comparing treatment results, especially how well the study treatment lowers virus levels and how many patients respond. The main target population is adults with chronic HCV infection.
Key points
- Clinical trial data for VELPATASVIR focus on chronic hepatitis C virus infection. The main study is a Phase 3 trial with 880 planned participants. It compares a treatment containing VELPATASVIR with another oral treatment in patients with HCV. The main outcome is whether HCV RNA drops below the lower limit of quantitation at study week 24. This means the trial is mainly checking how well the treatment controls the virus in the blood.
Trial overview
This article is based on one Phase 3 interventional trial that includes VELPATASVIR as part of a comparison treatment for people with chronic hepatitis C virus infection.
The study is titled as a comparison of whether BEM/RZR is similar to SOF/VEL in patients with hepatitis C virus infection.
The condition being studied is chronic Hepatitis C Virus (HCV) infection.
Who is being studied
The target population is people with chronic HCV infection.
The trial data do not give extra details about age limits, sex, or other entry rules, so only the condition-based population can be described from the source information.
Trial design and treatment comparison
This is an interventional study, which means researchers assign study treatment and then measure the results.
The brief summary says the trial is evaluating the efficacy of BEM/RZR fixed dose combination given for 8 or 12 weeks once daily versus SOF/VEL given for 12 weeks once daily.
SOF/VEL is the comparator treatment named in the source data, and VELPATASVIR appears as part of that comparison regimen.
The trial is also described as comparing whether BEM/RZR is similar to SOF/VEL, which means the researchers want to see if the results are close enough to be considered comparable.
Main endpoint and what it means
The main endpoint is the proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.
In simple words, this measures how many people have virus levels so low that the test cannot measure them reliably at that time point.
This endpoint is used to judge how effective the study treatment is at reducing the virus in the blood.
Study status and size
The trial status is Authorised.
The planned enrollment is 880 participants, which means the study is designed to include a large group of people.
A larger trial can help researchers compare treatment results more reliably.
Patient glossary for this study
- HCV: short for hepatitis C virus, the virus that causes the infection being studied.
- RNA: the genetic material of the virus measured in blood tests.
- LLOQ: the lowest amount a test can measure with confidence.
- Once daily: taken one time each day.
- Fixed dose combination: two medicines combined into one treatment product.
- Comparator: the treatment used for comparison in a trial.